News

Collaborating to produce the global MSIF research news

22 August 2017

MS Research Australia are very proud to have been approached by the MS International Federation (MSIF) to write the research articles for their monthly global research newsletter called MS Research News over the next few months.

MSIF is a unique global network of over 49 MS organisations, people affected by MS, volunteers and staff from around the world who share a vision of a world without MS.

To be given this opportunity to strengthen our involvement with MSIF is an honour for MS Research Australia. It demonstrates the international trust and respect shown for our organisation, as well as recognition of our willingness to readily collaborate with other organisations in the global mission to find a cure for MS.

Peer Baneke, CEO MSIF said ‘Through participating in this collaboration MS Research Australia are leading the way in making the global MSIF movement’s strategy a reality in relation to this and in so many other ways. MS Research Australia are setting a superb example which we will use as much as we can inside the movement to get as many of the other member organisations to join in on research and other global challenges’.

Global collaborations are a significant part of MS Research Australia’s strategic plan and we are looking forward to working with MSIF to bring accessible research news directly to MS organisations from around the world to help ensure that the huge world-wide research effort and advances in MS are shared as widely as possible.

The MSIF MS Research News is a monthly e-newsletter. To subscribe to this global communication please visit http://newsletters.msif.org/

Related News

Media Release

Early results show world-first adaptive trial in action for progressive MS

17 September 2026

A potential treatment for progressive multiple sclerosis (MS) will continue in a world-first multi-arm, multi-stage adaptive trial after showing encouraging early signs, with recruitment set to expand across Australia.

MS News

Alpha lipoic acid shows promise in Stage 1 of Octopus trial in progressive MS

17 September 2026

Results from Stage 1 of the Octopus trial find one of the trial treatments, alpha lipoic acid, shows promise in progressive MS and will continue into trial Stage 2.

MS News

Women and MS: one of the disease’s biggest mysteries

9 September 2026

Why does MS affect women more often than men? How does female biology impact MS activity? Discover what recent research is revealing about risk, hormones, immunity and EBV.

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

Collaborating to produce the global MSIF research news